Obesity
Commentary
Will new guidelines widen the gap in treating childhood obesity?
Those aware of the access barriers to the recommended obesity treatments worry about the consequences that the new guidelines will have in the...
From the Journals
Factors linked with increased VTE risk in COVID outpatients
While the overall risk for VTE was low, age of at least 55 years, being male, and having a BMI of at least 30 and history of VTE increased the...
From the Journals
Treat together: Tackle heart disease and obesity simultaneously
A new review outlines how obesity can impair common imaging tests used to diagnose heart disease.
Commentary
What’s it like to take Ozempic? A doctor’s own story
‘With the rising popularity of weight loss drug injections, I’ve received many questions from patients about the pros, cons, and costs,” doctor...
From the Journals
Causal link found between childhood obesity and adult-onset diabetes
Bigger children have increased risks for almost all subtypes of adult-onset diabetes, a Mendelian randomization study indicates.
Latest News
Troubling trend as both diabetes types rise among U.S. youth
Peak incidence of type 1 diabetes occurred at age 10 years, while for type 2 diabetes, the peak was at 16 years.
From the Journals
New insight into preventing antipsychotic-induced weight gain
Study found significant dose-response associations for weight and metabolic variables, with a unique signature for each antipsychotic.
From the Journals
Keto/paleo diets ‘lower quality than others,’ and bad for planet
Both keto and paleo diets tend to be higher in animal foods and lower in plant foods than other popular diets.
Case Reports
44-year-old man • elevated total cholesterol • chest pains • ketogenic diet • Dx?
► Elevated total cholesterol
► Chest pains
► Ketogenic diet
From the Journals
What happens if we sit for more than 8 hours per day?
“We used to believe that any intense physical exercise could compensate for a sedentary life,” says expert.
From the Journals
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
Only 9% of eligible adults with T2D received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020, in a new analysis.